Firma ProtaGene, Autor bei News-Research

ProtaGene Announces Strategic Partnership with the Life Science business of Merck to Expand Comprehensive Biologics Testing Solutions

18. Mai 2026 Firma ProtaGenePosted in AllgemeinTagged ??strategic, biologics, commercialization, contract testing, drug development, global network, life science, merck, Operational efficiency, partnership, Project Management, protagene, protein characterization, Regulatory Compliance, scientific excellence

ProtaGene today announced a strategic partnership with the Life Science business of Merck, which operates as MilliporeSigma in the United States and Canada, to provide biopharmaceutical customers with an end-to-end […]

Effector Function in Biologics: Why ADCC, CDC and Cell-Based Potency Assays Define True Therapeutic Performance

26. März 2026 Firma ProtaGenePosted in AllgemeinTagged assay, biologic, biosimilar, bispecifics, cell, cells, clinical, company, dose, lab, mask, new, protagene, webinar, with

The development of modern biologics has significantly expanded the therapeutic possibilities of monoclonal antibodies and related modalities. However, with increasing complexity, the requirements for their functional characterization have evolved as […]

New Capital Strengthens ProtaGene’s Advanced Analytical Leadership in the Biologics and Cell and Gene Therapy Markets

22. November 202326. Januar 2026 Firma ProtaGenePosted in AllgemeinTagged ampersand, analytics, biologics, biosimilars, cell, cmc, cro, discovery, disease, gene, lab, patients, protagene, research, therapy

ProtaGene, a leading global contract research organization (CRO) dedicated to advanced analytics for biologics and cell and gene therapies, today announced additional investment from Ampersand Capital Partners. Given the critical […]

Confronting Molecular Bioanalysis Challenges in Gene Therapy Development

19. Oktober 202326. Januar 2026 Firma ProtaGenePosted in AllgemeinTagged assay, cell, clinical, cmc, development, gene, genomics, pcr, regualtory, therapy

As the gene therapy sector continues to mature, regulators’ expectations for more robust product understanding are growing. It’s exciting to be part of today’s gene therapy development community; however, three […]

Navigating CMC Challenges in NBE and Therapeutic Antibody Development

11. September 202326. Januar 2026 Firma ProtaGenePosted in AllgemeinTagged antibody, biotech, bipharma, development, drug, mab, Pharma, protagene, research, therapy

In April 2021, the FDA approved the 100th monoclonal antibody as a therapeutic entity, a milestone that took 35 years to reach. As of the fall of 2022, the FDA […]

ProtaGene Appoints New Scientific and Commercial Leadership to Support Evolving Needs of Biologic and Cell & Gene Therapy Innovators

1. Februar 202326. Januar 2026 Firma ProtaGenePosted in AllgemeinTagged bioanalytix, cell, cmc, genewerk, indigo, labcorp, market, new, patients, protagen, protagene, research, therapy, thermo, with

ProtaGene GmbH, a leading global contract research organization focused on advanced analytics in biologics and cell and gene therapy, announced today the appointment of Jennifer Chadwick, Ph.D., as Chief Scientific […]

Foundation for the Industry’s Next-stage Innovation and Growth

6. Juli 202226. Januar 2026 Firma ProtaGenePosted in AllgemeinTagged analysis, analytics, drug, gene, genewerk, lab, labs, new, project, protagene, protein, storage, therapy, vector, with

ProtaGene is thrilled to announce the planned opening of our brand-new, state-of-the-art lab and office headquarters in the Burlington BioCenter, located in Boston’s rapidly growing biotechnology hub. Our expanded footprint […]